RT Journal Article
T1 Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
A1 Balaz, David
A1 Erick Wikman-Jorgensen, Philip
A1 Giner Galvan, Vicente
A1 Rubio-Rivas, Manuel
A1 de Miguel Campo, Borja
A1 Noureddine Lopez, Mariam
A1 Lopez Caleya, Juan Francisco
A1 Gomez Huelgas, Ricardo
A1 Pesqueira Fontan, Paula Maria
A1 Mendez Bailon, Manuel
A1 Fernandez-Garces, Mar
A1 Fernandez Cruz, Ana
A1 Garcia Garcia, Gema Maria
A1 Rhyman, Nicolas
A1 Corral-Gudino, Luis
A1 Lozano Rodriguez-Mancheno, Aquiles
A1 Navarro De La Chica, Maria
A1 Torregrosa Garcia, Andrea
A1 Nicolas Alcala, Jose
A1 Diaz Jimenez, Pablo
A1 Royo Trallero, Leticia Esther
A1 Comas Casanova, Pere
A1 Millan Nunez-Cortes, Jesus
A1 Casas-Rojo, Jose-Manuel
A1 SEMI-COVID-19 Network, 
K1 COVID-19
K1 corticosteroids
K1 Spain
K1 comorbidities
K1 Sars
AB Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p
PB Mdpi
YR 2021
FD 2021-10-01
LK https://hdl.handle.net/10668/25960
UL https://hdl.handle.net/10668/25960
LA en
DS RISalud
RD Apr 4, 2025